NCT06570096 is a NA clinical trial of Lidocaine 2% then bupivacaine 0.5% in Premixed, sponsored by Tanta University.

Who is sponsoring NCT06570096?

NCT06570096 is sponsored by Tanta University.

What drugs are being tested in NCT06570096?

Interventions in NCT06570096: Lidocaine 2% then bupivacaine 0.5%, Lidocaine 2% and bupivacaine 0.5%.

What condition does NCT06570096 study?

NCT06570096 studies Premixed, Sequential, Lidocaine, Bupivacaine, Supraclavicular Brachial Plexus Block, Arteriovenous Fistula.

Is NCT06570096 still recruiting?

NCT06570096 is currently completed. Last updated 8 April 2025.

Last reviewed 2025-04-08 · How we verify

NCT06570096

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Premixed vs Sequential Injections of Lidocaine and Bupivacaine for Supraclavicular Brachial Plexus Block in Patients Undergoing Arteriovenous Fistula Creation

Completed NA Last updated 8 April 2025

What this trial tests

NA trial testing Lidocaine 2% then bupivacaine 0.5% in Premixed in 100 participants. Completed in 16 March 2025.

Timeline

24 August 2024

Primary endpoint
16 March 2025

16 March 2025

Quick facts

Lead sponsor	Tanta University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	100
Start date	24 August 2024
Primary completion	16 March 2025
Estimated completion	16 March 2025
Sites	1 location across Egypt

Drugs / interventions tested

Lidocaine 2% then bupivacaine 0.5% — full drug profile →
Lidocaine 2% and bupivacaine 0.5% — full drug profile →

Conditions studied

Premixed — all drugs for Premixed →
Sequential — all drugs for Sequential →
Lidocaine — all drugs for Lidocaine →
Bupivacaine — all drugs for Bupivacaine →

Sponsor

Tanta University

Who can join

Adults 18 to 65, any sex, with Premixed or Sequential. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to compare premixed and sequential injections of lidocaine and bupivacaine for supraclavicular brachial plexus block in patients undergoing arteriovenous fistula creation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Tanta University trials

Trials by the same sponsor.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06570096 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tanta University
Last refreshed: 8 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06570096.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing